Immunome (NASDAQ: IMNM) revenue
Immunome reported revenue of $6.9m for fiscal 2025, 23.2% less than in fiscal 2024 ($9.0m). Since fiscal 2019 its revenue has grown by 69,310.0%, an average growth of 197.6% a year.
Immunome's revenue has fallen for 2 years in a row, and its best year of the last 5 was fiscal 2023. The biggest drop was in fiscal 2020, −90.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $6.9m | −23.2% | −$224.1m | −3,228.8% |
| 2024 | $9.0m | −35.5% | −$305.8m | −3,382.4% |
| 2023 | $14.0m | — | −$109.5m | −781.4% |
| 2020 | $0.0m | −90.0% | −$12.3m | −1,226,100.0% |
| 2019 | $0.0m | — | −$10.3m | −103,480.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunome revenue compared with its sector
By revenue for its latest fiscal year, Immunome ranks 378th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Immunome, −23.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 376th | Ovid Therapeutics | $7.3m | 1,181.3% |
| 377th | Whitehawk Therapeutics | $7.1m | −72.5% |
| 378th | Immunome | $6.9m | −23.2% |
| 379th | Korro Bio | $6.4m | 181.5% |
| 380th | Abeona Therapeutics | $5.8m | 37.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Immunome
- How much revenue did Immunome make in fiscal 2025?
- Immunome reported revenue of $6.9m for fiscal 2025, compared with $9.0m in fiscal 2024.
- How much has the revenue of Immunome grown?
- Between fiscal 2019 and fiscal 2025 it went from $0.0m to $6.9m: 69,310.0% more, an average growth of 197.6% a year.
- What was the best year for revenue at Immunome?
- Of its last 5 fiscal years, fiscal 2023, with $14.0m.
- Where does Immunome rank in its sector by revenue?
- It ranks 378th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Immunome come from?
- From the annual report (Form 10-K) that Immunome files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunome files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2020 · 2019. More on Immunome: the Immunome page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.